Why some cancers are curable by chemotherapy while most are not is an enigma and a major challenge for cancer researchers. The use of anticancer drugs in appropriate dosages and combinations has improved response rates and prolonged life. Yet, it is not uncommon for a patient to have a relapse during a course of chemotherapy that was initially successful. The discovery more than a decade ago that resistance to unrelated drugs is relatively common among variant cells isolated in vitro has led to speculations that similar multidrug-resistant (MDR) tumor cells arise in vivo and that selective growth of such cells leads to a disease that is nonresponsive even to a combination of different anticancer drugs (1) . That such a scenario might account for the lack of response observed in some patients has spawned an area of active research (a) to elucidate the mechanism of multidrug resistance and (b) to test critically the hypothesis that the presence of MDR tumor cells limits successful chemotherapy.
In vitro gene-transfection studies have provided compelling evidence that increased levels of P-glycoprotein are sufficient for, and are causes of, multidrug resistance (2-4). P-glycoprotein is thought to function as an energy-dependent, drug efflux pump of broad specificity, mediating resistance to unrelated agents. Thus the use of molecular probes to detect P-glycoprotein gene expression in biopsy samples appears to be appropriate for detecting MDR cells in human tumors.
The initial study by Bell et al. (5) using immunoblot analysis showed that cells from some advanced nonresponsive ovarian cancers possessed increased P-glycoprotein. Subsequently, studying a series of sequential biopsy specimens from two patients with acute nonlymphoblastic leukemia, Ma et al. (6) found increased proportions of blast cells that stained positive for P-glycoprotein, correlating with disease progression. Gerlach et al. (7) determined that approximately 20% of the biopsy specimens from adult patients with sarcoma expressed detectable levels of P-glycoprotein; however, surprisingly, a significant proportion of the positive samples were from patients who had had no prior chemotherapy.
The article by Goldstein et al. in this issue of the journal is an impressive extension of these earlier findings. Using the human MDR1 cDNA probe to detect P-glycoprotein expression, Goldstein et al. analyzed over 400 tumor samples from a wide range of human malignancies. The significant conclusion drawn from this study is that P-glycoprotein expression can be detected in human cancers of all types (e.g., carcinomas, lymphomas, and leukemias).
How can these data be interpreted within the context of whether or not the presence of MDR tumor cells affects the response of the patient? Goldstein et al. point out that factors such as tumor heterogeneity preclude a simple answer at this time. Even though certain traditionally nonresponsive tumors, e.g., adrenocortical cancer and colon cancer, tend to express high levels of MDR1 mRNA, there is still a wide range of expression within these tumor types. There are no data relating the level of P-glycoprotein expression for a given malignancy to the ability of the tumor cells to survive a particular course of chemotherapy in patients. Thus it is not clear at this point whether the classification of low and high levels of P-glycoprotein mRNA, as defined by Goldstein et al., will eventually prove to be prognostic clinically. Prospective studies of P-glycoprotein levels with progression of the disease in individuals will certainly be necessary before some of these questions can be answered.
Recent findings indicating that normal tissues also express P-glycoprotein in different amounts further complicate the interpretation of P-glycoprotein expression in tumor cells. What the normal role of P-glycoprotein is, however, is debatable,, although it has been suggested that it functions as a generalized detoxification system. Nevertheless, its expression is likely to correlate with a differentiated state. Thus certain types of tumor cells expressing high levels of P-glycoprotein may have a more differentiated phenotype, and they are not necessarily the important malignant cells at risk. The situation is further complicated by the discovery that human cells contain two P-glycoprotein genes [mdrl (also known as MDR1 and PGY1) and mdr3 (also known as MDR2)] that are differentially expressed in normal tissues (8,9). It is not known at present if both genes are important in the development of tumor cell malignancy. Does P-glycoprotein predict response to chemotherapy? Studies of different malignancies may yield different answers to this critical question. What is at stake, however, is the potential of early detection of a nonresponsive disease, of circumvention by use of chemosensitizers, of new drugs and modalities, and of a rational approach to chemotherapy for a wide range of malignancies. These possibilities should be sufficient to encourage further studies. The work of Goldstein et al. has given us the framework and an appreciation of the magnitude of the task necessary to answer this question.
